Skip to content
Search

Latest Stories

Submit Guest Post

Vistara launches more flights to Coimbatore

Vistara is a joint venture of Tata group and Singapore Airlines

Vistara launches more flights to Coimbatore

INDIAN airline Vistara on Friday (20) started daily direct flights between the capital Delhi and Coimbatore in southern India, the company said in a statement. 

The airline will also start daily direct service on the Mumbai-Coimbatore route from Friday (27) and double the daily flights on the Bengaluru-Coimbatore route starting 3 June, the statement added.


The Delhi-Coimbatore flight is at 11.45 am and the return flight starts at 3.15 pm (IST). The Mumbai-Coimbatore flight departs at 11.10 am and at 1.30 pm the return flight leaves the southern city.

The two daily flights start from Bengaluru at 7 am and 7.25 pm respectively. The flight timings from Coimbatore are 8.30 am and 8.55 pm, the company said.

“The launch of daily direct flights to Coimbatore from three metro cities, at very convenient departure and arrival timings, is an important step towards offering more connections to our customers and densifying our domestic network," said Vinod Kannan, chief executive officer, Vistara.

"With Coimbatore emerging as a key hub for trade and commerce besides being a preferred tourist destination, it’s a city that the discerning travellers are increasingly flying to, giving us the opportunity to offer them our award-winning services on these routes too.”

Vistara, a joint venture of Tata group and Singapore Airlines, is India’s highest-rated airline on Skytrax and TripAdvisor, the company claimed.

Add EasternEye As Your Trusted Source
preferred source on google news

More For You

AstraZeneca

AstraZeneca chief executive Pascal Soriot says the company has the science, pipeline and team to deliver its long-term growth ambitions

Getty Images

AstraZeneca targets $80bn revenue by 2030 with $1.5bn savings and pipeline investment

  • AstraZeneca expects its restructuring programme to generate $1.5bn in annualised savings by 2029, with most of the money reinvested in research and development.
  • The plan could incur up to $2bn in one-off restructuring costs, although the company expects its overall workforce to continue growing.
  • Third-quarter revenue rose 7 per cent to $16.21bn, while oncology sales increased 17 per cent to $7.77bn.

AstraZeneca has unveiled plans to generate around $1.5bn in annual savings through a three-year restructuring programme, as chief executive Pascal Soriot shifts the focus back to growth and investment in its drug pipeline.

The British-based pharmaceutical group said its Reshaping for Sustainable Growth programme would redirect resources towards research and development, particularly its pipeline of more than 180 projects and emerging technologies.

Keep ReadingShow less